A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects With Primary Biliary Cholangitis
Latest Information Update: 28 Jan 2025
At a glance
- Drugs Bezafibrate/obeticholic acid (Primary)
- Indications Primary biliary cirrhosis
- Focus Adverse reactions; Registrational
- Sponsors Intercept Pharmaceuticals
- 02 Oct 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2029.
- 02 Oct 2024 Status changed from not yet recruiting to recruiting.
- 16 Jul 2024 New trial record